Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.16 Bil Enterprise Value: 9.58 Bil PE Ratio: 106.36 PB Ratio: 2.73 GF Score: 85/100

Qiagen NV at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 09, 2021 / 02:45PM GMT
Release Date Price: €41.25 (+0.67%)
Luke England Sergott
Barclays Bank PLC, Research Division - Research Analyst

All right. Hi, everybody. Luke Sergott from Barclays. I cover life science tools diagnostics here. It is almost my true pleasure to have John Gilardi from QIAGEN with us. He seems to have mailed me all the weight he has lost.

So with that, I'll let him kind of give an open introduction into the company and speak a little bit, and then we can dive into some questions.

John Gilardi
QIAGEN N.V. - VP of Corporate Communications & IR

Thanks, Luke. It's unfortunate that we can't be together in Miami, given that this would have been your first Barclays Conference in Miami, but it's still great to see you in the new seat, and thanks for having us here.

As for QIAGEN, what I would say is that we're off to a strong start in 2021. You saw us end 2020, exceeding the goals that we had set for the year, driven by COVID testing demand as well as improving trends in the rest of our portfolio. We're looking for another year of strong growth in 2021, looking for 18% to 20% CER

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot